I nā makahiki i hala iho nei, ke kūʻai aku nei oapixabanua ulu wikiwiki, a ua ʻoi aku ka mākeke honuarivaroxaban. No ka mea ʻo Eliquis (apixaban) he ʻoi aku ka maikaʻi ma mua o warfarin i ka pale ʻana i ka hahau a me ke koko, a me Xarelto (Rivaroxaban) hōʻike wale i ka haʻahaʻa ʻole. Kahi mea hou aʻe,ʻO Apixabanʻaʻole koi i nā hoʻoponopono dosage paʻakikī, a ʻoi aku ka maʻalahi o ka lāʻau. ʻO kēia pūʻulu o nā hemahema i hana ʻiarivaroxabane lilo i wahi ma ka mākeke US.

Eia naʻe, ma ka ʻāina nui o Kina,rivaroxabanloaʻa nā hōʻailona hou aʻe ma ka honua a ma ka ʻāina nui o Kina. ʻO ka manawa pau o ka patentrivaroxabankokoke, a hiki i ka loaʻa ʻana o ka lāʻau lapaʻau ke kumu o ka heluna kanaka orivaroxabanʻO nā lāʻau lapaʻau maʻamau e ʻoi aku ma mua o kēlāʻO Apixaban.

Wahi a Xianda data, ʻo ke kūʻai aku ʻana o ka mākeke kūloko o rivaroxaban ma 2018 he 2.8 biliona yuan. Wahi a ka hoʻolaha ʻana o Huahai Pharmaceutical, ke kūʻai aku ʻana o ka mākeke halemai kūlokorivaroxabanma 2018 he 1.527 biliona yuan.

ʻOiaʻiʻo, ʻo ka papa inoa o nā lāʻau lapaʻau e alakaʻi i kahi hāʻule nui o ke kumu kūʻai o ka lā hoʻokahirivaroxaban. Me ka noʻonoʻo ʻana i waena o nā NOAC āpau, nā patent norivaroxabanpau nā pūhui i ka makahiki 2020 ma mua loa (ʻo nā patents noapixabana ʻoi aku ka lōʻihi o ka dabigatran etexilate no ka manawa lōʻihi), he mea kānalua ia e pōmaikaʻi i ka hoʻolaha piha ʻana orivaroxabannā lāʻau maʻamau e pani i ka warfarin. Inā ke kumu kūʻai o kēlā me kēia lā orivaroxabanHoʻokuʻu ʻia nā lāʻau lapaʻau maʻamau mai 27.6 yuan a i 2.76 yuan, e hoʻoikaika pū ʻia kēia ʻano.

ʻO ka nui o nā noi e noʻonoʻo wale i nā mea maʻi me ka atrial fibrillation (AF) he mea kupanaha hoʻi. ʻO ka nui o nā maʻi me ka atrial fibrillation ma Kina ma kahi o 10 miliona, a ma kahi o 2 miliona no ka fibrillation atrial valvular a ma kahi o 7 miliona no ka fibrillation atrial non-valvular. Nānā ma 2016 Ua ʻike ʻia ʻo ka ʻike o ka fibrillation atrial ma Mainland Kina he 40%, a ʻo ka helu anticoagulation he 30%. Maʻalahi ka hoʻohana ʻana o Rivaroxaban, ʻaʻole koi i ka nānā maʻamau o nā hōʻailona coagulation, a e hoʻomaikaʻi nui ʻia ka helu anticoagulation. Ua wānana ʻia ka lāʻau lapaʻau maʻamau orivaroxabanaia ma Mainland Kina. ʻO ka nui o ka mākeke i hoʻohana ʻia i nā maʻi me ka fibrillation atrial non-valvular a me ka fibrillation atrial: 7 miliona mau maʻi * 30% anticoagulation rate * 50% penetration rate * 2.76 yuan / lā * 365 mau lā = 157 miliona yuan.

Eia kekahi, ua hoʻohaʻahaʻa ʻia ka manaʻo o ka mākeke no ka pale ʻana a me ka mālama ʻana i nā mea maʻi VTE. Wahi a ka helu helu o ka VTE Prevention and Treatment Center ma ʻAmelika Hui Pū ʻIa, ʻo ka nui o nā maʻi VTE ma ʻAmelika Hui Pū ʻIa he 900,000 i kēlā me kēia makahiki, a ʻo ka nui o ka poʻe i make i ka VTE hiki i ka 60,000 a 100,000, a aia kekahi. ʻO nā pilikia lōʻihi (Pēlā me DVT) he 50% ka poʻe maʻi, a ʻo ka helu o nā relapses i loko o 10 mau makahiki i helu ʻia. no 33%.

Ma muli o ka ʻelemakule o Kina, a ʻoi aku ka nui o ka heluna kanaka ma mua o 4 mau manawa i ko ʻAmelika Hui Pū ʻIa (1.395 biliona kānaka). Hiki ke wānana ʻia aia he 3.6 miliona mau maʻi VTE ma Kina i kēlā me kēia makahiki. Ke manaʻo nei ʻo ka 3 mau mahina lapaʻau orivaroxabanʻO 80%, ka nui o ka mākeke: 3.6 miliona mau maʻi * 80% lāʻau lapaʻau * 2.76 yuan / lā * 92 lā = 731 miliona yuan.

No laila, ke helu wale nei i nā hōʻailona ʻelua o AF a me VTE, ʻo ka nui o ka mākeke kūloko o nā lāʻau lapaʻau generic rivaroxaban kokoke i 2 biliona yuan. Ua lawa ia i mea e holo wikiwiki ai nā hui lāʻau lapaʻau kūloko e noi no ka papa inoa.

mākou,Hale Hana Laau Laau o Changzhou, hana pūapxiabanarivaroxban, a loaʻa iā lāua ʻelua DMF.Rivaroxabanaia ma lalo o ka hana no ka noi ʻana iā CEP a me WC.